5AM Venture Management
Latest statistics and disclosures from 5AM Venture Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ELVN, TRDA, DNTH, MRUS, CLDX, and represent 47.64% of 5AM Venture Management's stock portfolio.
- Added to shares of these 9 stocks: PRAX (+$21M), CNTA (+$14M), SLN (+$10M), Adverum Biotechnologies (+$7.7M), TYRA (+$6.3M), Q32 Bio, VRDN, GHRS, MRUS.
- Started 5 new stock positions in Adverum Biotechnologies, CNTA, SLN, PRAX, Q32 Bio.
- Reduced shares in these 9 stocks: VKTX (-$29M), ELVN (-$23M), IRON (-$17M), Mirati Therapeutics (-$11M), SPRB (-$6.9M), DNTH (-$6.9M), BHVN, Homology Medicines, MLTX.
- Sold out of its positions in IRON, Homology Medicines, Mirati Therapeutics, SPRB.
- 5AM Venture Management was a net seller of stock by $-33M.
- 5AM Venture Management has $447M in assets under management (AUM), dropping by 18.47%.
- Central Index Key (CIK): 0001799883
Tip: Access up to 7 years of quarterly data
Positions held by 5AM Venture Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for 5AM Venture Management
5AM Venture Management holds 26 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Enliven Therapeutics (ELVN) | 15.1 | $68M | -25% | 3.8M | 17.59 |
|
| Entrada Therapeutics (TRDA) | 14.0 | $63M | 4.4M | 14.17 |
|
|
| Dianthus Therapeutics (DNTH) | 8.3 | $37M | -15% | 1.2M | 30.00 |
|
| Merus N V (MRUS) | 5.5 | $25M | +5% | 549k | 45.03 |
|
| Celldex Therapeutics Com New (CLDX) | 4.7 | $21M | 497k | 41.97 |
|
|
| Praxis Precision Medicines I Com New (PRAX) | 4.6 | $21M | NEW | 340k | 61.02 |
|
| Viking Therapeutics (VKTX) | 4.4 | $20M | -59% | 238k | 82.00 |
|
| Pharvaris N V (PHVS) | 4.1 | $18M | 798k | 23.11 |
|
|
| Biohaven (BHVN) | 3.9 | $18M | -20% | 320k | 54.69 |
|
| Avidity Biosciences Ord (RNA) | 3.8 | $17M | 666k | 25.52 |
|
|
| Tyra Biosciences (TYRA) | 3.4 | $15M | +69% | 939k | 16.40 |
|
| Vor Biopharma (VOR) | 3.4 | $15M | 6.4M | 2.37 |
|
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 3.2 | $14M | -6% | 282k | 50.23 |
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 3.1 | $14M | NEW | 1.2M | 11.30 |
|
| Miragen Therapeutics (VRDN) | 2.9 | $13M | +25% | 737k | 17.51 |
|
| Silence Therapeutics Ads (SLN) | 2.3 | $10M | NEW | 476k | 21.60 |
|
| Anaptysbio Inc Common (ANAB) | 1.8 | $8.1M | 358k | 22.52 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 1.7 | $7.7M | 490k | 15.76 |
|
|
| Adverum Biotechnologies Com New | 1.7 | $7.7M | NEW | 542k | 14.14 |
|
| Rallybio Corp (RLYB) | 1.5 | $6.7M | 3.6M | 1.85 |
|
|
| Gh Research Ordinary Shares (GHRS) | 1.4 | $6.1M | +41% | 573k | 10.66 |
|
| Scpharmaceuticals (SCPH) | 1.3 | $6.0M | 1.2M | 5.02 |
|
|
| Mersana Therapeutics (MRSN) | 1.3 | $5.8M | 1.3M | 4.48 |
|
|
| Cogent Biosciences (COGT) | 1.2 | $5.3M | 790k | 6.72 |
|
|
| Q32 Bio | 1.0 | $4.3M | NEW | 252k | 17.04 |
|
| Cidara Therapeutics Inc Common Stock Usd 0.0001 (CDTX) | 0.2 | $1.0M | 1.1M | 0.92 |
|
Past Filings by 5AM Venture Management
SEC 13F filings are viewable for 5AM Venture Management going back to 2019
- 5AM Venture Management 2024 Q1 filed May 15, 2024
- 5AM Venture Management 2023 Q4 filed Feb. 14, 2024
- 5AM Venture Management 2023 Q3 filed Nov. 14, 2023
- 5AM Venture Management 2023 Q2 filed Aug. 14, 2023
- 5AM Venture Management 2023 Q1 filed May 15, 2023
- 5AM Venture Management 2022 Q4 filed Feb. 14, 2023
- 5AM Venture Management 2022 Q3 filed Nov. 14, 2022
- 5AM Venture Management 2022 Q2 filed Aug. 15, 2022
- 5AM Venture Management 2022 Q1 filed May 16, 2022
- 5AM Venture Management 2021 Q4 filed Feb. 3, 2022
- 5AM Venture Management 2021 Q3 filed Nov. 15, 2021
- 5AM Venture Management 2021 Q2 filed Aug. 16, 2021
- 5AM Venture Management 2021 Q1 filed May 17, 2021
- 5AM Venture Management 2020 Q4 filed Feb. 16, 2021
- 5AM Venture Management 2020 Q3 filed Nov. 16, 2020
- 5AM Venture Management 2020 Q2 filed Aug. 5, 2020